| Hyperlipidemia
Lipitor vs Zypitamag
Side-by-side clinical, coverage, and cost comparison for hyperlipidemia.Deep comparison between: Lipitor vs Zypitamag with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZypitamag has a higher rate of injection site reactions vs Lipitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zypitamag but not Lipitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lipitor
Zypitamag
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor (statin)
Oral
Daily
HMG-CoA reductase inhibitor
Indications
- Myocardial Infarction
- Cerebrovascular accident
- Stable angina
- Diabetes Mellitus, Non-Insulin-Dependent
- Congestive heart failure
- Hyperlipidemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
- Hyperlipidemia
Dosing
Myocardial Infarction, Cerebrovascular accident, Stable angina, Diabetes Mellitus Non-Insulin-Dependent, Congestive heart failure, Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia 10 or 20 mg once daily starting; range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily; oral.
Familial hypercholesterolemia - heterozygous Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10 mg once daily starting, range 10-20 mg once daily; oral.
Homozygous Familial Hypercholesterolemia Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10-20 mg once daily starting, range 10-80 mg once daily; oral.
Hyperlipidemia 2 mg to 4 mg orally once daily; recommended starting dose for moderate/severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily (use alternative pitavastatin formulation), maximum 2 mg once daily; do not exceed 1 mg once daily with erythromycin; do not exceed 2 mg once daily with rifampin.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient in Lipitor
- Concomitant use of cyclosporine
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to pitavastatin or any excipients in ZYPITAMAG
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, myasthenia gravis exacerbation, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=2%) Myalgia, constipation, diarrhea, back pain, pain in extremity
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, fatigue, malaise, dizziness, hepatitis, jaundice, fatal and non-fatal hepatic failure, angioedema, muscle spasms, myopathy, rhabdomyolysis, hypoesthesia, peripheral neuropathy, cognitive impairment, insomnia, depression, erectile dysfunction, interstitial lung disease, lichen planus
Pharmacology
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol; it lowers plasma LDL cholesterol and lipoprotein levels by inhibiting hepatic cholesterol synthesis and upregulating LDL receptor expression on hepatic cell surfaces.
Pitavastatin is an HMG-CoA reductase inhibitor that blocks the conversion of HMG-CoA to mevalonate, a rate-limiting step in cholesterol biosynthesis, thereby upregulating LDL receptors, increasing LDL uptake by the liver, and reducing plasma LDL-C and VLDL levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lipitor
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (1/12)
Zypitamag
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Lipitor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zypitamag
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Lipitor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Zypitamag
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lipitor.
No savings programs available for Zypitamag.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LipitorView full Lipitor profile
ZypitamagView full Zypitamag profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.